$ARTL Presents ART26.12 Human Metabolite #Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success ir.artelobio.com/news-events…

FABP5 was recently featured as a potential new therapeutic target for #pain in the European Journal of Pain @EFICPain This paper shifts the paradigm: - Pain is not just neuronal—it’s lipid signaling dysregulation - FABP5 sits upstream of multiple pain pathways - Modulating FABP5 enables system-wide effects Unlike opioids (single receptor), this approach: - Rebalances endogenous signaling - Expands therapeutic reach - May reduce tolerance risk ART26.12 is $ARTL's #FABP5 inhibitor being developed to treat the network—not just the signal—in neuropathic pain. Read the publication here: onlinelibrary.wiley.com/doi/…

$ARTL Announces Strategic Collaboration with Artificial Intelligence (#AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development @sciencemachine ir.artelobio.com/news-events…

$ARTL Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel #Pain Treatment with a Potentially First-in-Class Profile ir.artelobio.com/news-events…

Evaluating FABP5 as a Therapeutic Target for Pain Management - Warren - 2026 - European Journal of Pain - Wiley Online Library onlinelibrary.wiley.com/doi/…

$ARTL's ART26.12, Non-Opioid Pain Therapy Discovered at Stony Brook @stonybrooku, Advances with $11 Million Private Investment news.stonybrook.edu/universi…

$ARTL Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments ir.artelobio.com/news-events… #GLP1

$ARTL Expansion into $16.3B #Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength ir.artelobio.com/news-events…

$ARTL Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in #Glaucoma Patients ir.artelobio.com/news-events…

$ARTL commends Presidential Executive Order expanding #CBD #Research and access, highlights next-gen CBD #cocrystal ART12.11 ir.artelobio.com/news-events…

$ARTL Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (#FABP5) Inhibitor Significantly Reduces Stress-Induced #Anxiety and #Depression Behaviors in Preclinical Models ir.artelobio.com/news-events…

Great to see @pfizer highlighting cachexia and its devastating impact on people struggling with chronic illnesses, including cancer. youtube.com/shorts/UV49iGprR… via @YouTube

Cancer anorexia-cachexia syndrome (CACS) is a complex condition involving weight loss, lack of appetite, metabolic disruption, and reduced physical function. ART27.13 is designed to activate specific cannabinoid receptors involved in appetite, metabolism, activity, and body composition—all key pathways that contribute to #CACS. The interim Phase 2 #CAReS results showed encouraging signs across multiple meaningful measures, including weight, lean body mass, and activity levels—reinforcing the scientific rationale behind ART27.13’s multi-effect profile. Learn more about the CAReS interim data: artelobio.com/pipeline/art27…

$ARTL Provides Business Update and Reports Third Quarter 2025 Financial Results ir.artelobio.com/news-events…

$ARTL Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer ir.artelobio.com/news-events… #DrugDiscoveryToday #FABPs

Behind every data point is a person — someone fighting to stay strong, active, and hopeful during cancer treatment. Cancer anorexia-cachexia syndrome (#CACS) affects up to 80% of people with advanced #cancer, leading to profound weight and muscle loss, fatigue, and loss of independence. Interim Phase 2 #CAReS results with #ART27_13 showed encouraging improvements in weight, lean body mass, and activity levels — outcomes that could translate to more strength, better appetite, and improved #QualityOfLife for patients who need it most. Every step forward in this study may accomplish more than just a clinical milestone — we hope it’s also progress towards restoring strength, confidence, and dignity for people living with cancer. Learn more about the CAReS trial and our mission to make a difference: artelobio.com/pipeline/art27… #CancerCare #PatientImpact #ClinicalResearch #CancerSupport

$ARTL Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer ir.artelobio.com/news-events… #CFO